Vanguard Capital Management
AMLX icon

Vanguard Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Vanguard Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.9M Buy
4,224,224
+82,649
+2% +$1.28M ﹤0.01% 1709
2026
Q1 		$57.6M Buy
+4,141,575
New +$58.3M ﹤0.01% 1791

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Vanguard Capital Management's AMLX Position: Q2 2026 in Review

Vanguard Capital Management increased its Amylyx Pharmaceuticals (AMLX) stake by 2% in Q2 2026, buying an estimated $1.28M and bringing the position to 4,224,224 shares worth $75.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1709.

Vanguard Capital Management first reported a position in AMLX in Q1 2026 and has held it in 2 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Vanguard Capital Management held 4,224,224 shares of Amylyx Pharmaceuticals worth $75.9M as of Q2 2026.
  • Vanguard Capital Management bought 82,649 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.28M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1709 holding.
  • Vanguard Capital Management first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.